Trial Profile
A randomized, open labeled, multicenter study comparing entecavir versus lamivudine as antiviral prophylaxis for patients with hepatitis B infection undergoing cytotoxic chemotherapy for malignant tumors
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Entecavir (Primary) ; Lamivudine
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms APPLE
- 28 Jun 2017 Status changed from recruiting to completed.
- 03 May 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
- 17 Nov 2015 Planned End Date changed from 1 Dec 2014 to 1 Jun 2017 as reported by ClinicalTrials.gov record.